Illumina

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. 

CEO
Jacob Thaysen
CEOJacob Thaysen
Employees
10,370
Employees10,370
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
10,370
Employees10,370

ILMN Key Statistics

Market cap
14.74B
Market cap14.74B
Price-Earnings ratio
11.78
Price-Earnings ratio11.78
Dividend yield
Dividend yield
Average volume
1.60M
Average volume1.60M
High today
$98.70
High today$98.70
Low today
$93.14
Low today$93.14
Open price
$94.05
Open price$94.05
Volume
2.16M
Volume2.16M
52 Week high
$156.66
52 Week high$156.66
52 Week low
$68.70
52 Week low$68.70

ILMN News

TipRanks 1d
Illumina releases its novel 5-base solution

Illumina (ILMN) announced the release of its novel 5-base solution, enabling researchers to pursue broader biological questions with accuracy and ease. The 5-ba...

Simply Wall St 3d
Illumina: Exploring Valuation After BioInsight Launch and Renewed Strategic Ambitions

Illumina (ILMN) has launched BioInsight, a new business unit focused on integrating sequencing, software, and artificial intelligence to tackle large-scale mult...

Illumina: Exploring Valuation After BioInsight Launch and Renewed Strategic Ambitions
Simply Wall St 5d
Does ILMN’s BioInsight Launch Signal a New Chapter in Data-Driven Drug Discovery Strategy?

In early October 2025, Illumina announced the launch of BioInsight, a new business unit led by Rami Mehio focused on integrating artificial intelligence and mul...

Does ILMN’s BioInsight Launch Signal a New Chapter in Data-Driven Drug Discovery Strategy?

Analyst ratings

48%

of 23 ratings
Buy
39.1%
Hold
47.8%
Sell
13%

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.